Omni system provides 2-year sustained IOP control
Click Here to Manage Email Alerts
Key takeaways:
- Canaloplasty and trabeculotomy helped control IOP over 2 years.
- There were no device-related adverse events during follow-up.
Canaloplasty and trabeculotomy performed with the Omni surgical system provided patients with glaucoma with sustained IOP control over 2 years, according to a study published in Clinical Ophthalmology.
Study author Blake K. Williamson, MD, MPH, MS, told Healio/OSN that surgeons want a MIGS device that has immediate efficacy with a long-lasting effect.
“That’s been a question with the different MIGS devices and technologies that are on the market. How long can we delay progression of glaucoma?” he said. “It’s always great when you see early postop results, 1-year data, that actually hold true at the end of 2 years. The biggest thing with ROMEO that we were really excited to see was at the end of 2 years, you still had a statistically significant reduction in both IOP and the number of medications patients are taking.”
In an extension of the 12-month ROMEO study, 72 patients with mild to moderate glaucoma were stratified into two groups: baseline IOP greater than 18 mm Hg (group 1) and baseline IOP of 18 mm Hg or less (group 2). Eyes underwent canaloplasty and trabeculotomy with the Omni surgical system (Sight Sciences) combined with cataract surgery or as a stand-alone treatment.
The mean IOP at baseline was 18.1 mm Hg, and the mean number of medications was two.
At year 2, patients in group 1 who underwent combined treatment had a mean IOP of 15.6 mm Hg and were on 1.4 medications. Patients in group 1 who underwent stand-alone treatment had a mean IOP of 14.7 mm Hg and were on 1.6 medications.
Patients in group 2 who underwent combined treatment had a mean IOP of 13.7 mm Hg and were on 1.2 medications. Patients in group 2 who underwent stand-alone treatment had a mean IOP of 13.3 mm Hg and were on 1.2 medications.
After treatment, one-third of patients were medication-free compared with nine before surgery.
There were no device-related adverse events during follow-up. Six eyes needed additional surgery or laser intervention for IOP control after 12 months.
Williamson said the Omni system has become one of his go-to MIGS procedures for patients undergoing stand-alone treatment, but he also finds it particularly useful in patients with moderate to severe glaucoma who are undergoing cataract surgery.
“I find that it has a little more firepower, in terms of IOP lowering and medication reduction, than some of the other devices on the market that are, perhaps, geared more toward mild glaucoma patients,” Williamson said.
Collapse
Read more about
Click Here to Manage Email Alerts